Thank you, Madam Chair.
Gentlemen, thank you for having come here today.
What I understand from the fairly substantial presentations we have heard today is that you have been following this file for a number of years. I conclude that some of the elements of the current program could stand for some improvement, in your opinion.
Mr. Williams, in your presentation you seemed to be saying that for certain patients this program constitutes an obstacle to access to certain drugs. In your work in the field, did you have an opportunity to collect figures, to observe specific cases where this program proved very, very problematical for some patients or groups of patients?